Drug Type Interferons, Biosimilar |
Synonyms Recombinant Human Interferon α2b(P.putida), 重组人干扰素α2b注射液(天津未名生物), 安福隆 + [1] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 1997), |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| AIDS-related Kaposi Sarcoma | China | 01 Jan 1997 | |
| Chronic Myelogenous Leukemia | China | 01 Jan 1997 | |
| Condylomata Acuminata | China | 01 Jan 1997 | |
| Hairy Cell Leukemia | China | 01 Jan 1997 | |
| Hepatitis B, Chronic | China | 01 Jan 1997 | |
| Hepatitis C, Chronic | China | 01 Jan 1997 | |
| Lymphoma | China | 01 Jan 1997 | |
| Melanoma | China | 01 Jan 1997 | |
| Neoplasms | China | 01 Jan 1997 | |
| Virus Diseases | China | 01 Jan 1997 |






